April 27, 2021 06:00 AM EDT

After facing a 16-month sojourn during Covid to overcome a stunning CRL, little Enzyvant says it's back on track — expects marketing decision later this year

Back in late 2019, Enzyvant CEO Rachelle Jacques was shocked when the FDA issued a CRL for its therapy to treat ultra-rare cases of …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Af­ter fac­ing a 16-month so­journ dur­ing Covid to over­come a stun­ning CRL, lit­tle En­zy­vant says it's back on track — ex­pects mar­ket­ing de­ci­sion lat­er this year